Searched for
DRL STOCK FALL
Market Outlook: Rupak De’s top 3 trading stock picks for the week aheadGeopolitical tensions, rising crude oil, and a weakening rupee are fueling market volatility, according to Rupak De of LKP Securities. He n...- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Aggressive Fed hike fears send Sensex tumbling for 4th dayIT stocks were among the worst hit in today's session after earnings from Mindtree, HCL Tech and TCS failed to cheer the Street. The Nifty ...
- Dr Reddy's strong product pipeline and other factors that make it stock pick of the weekDRL continues to generate free cash flows (FCFs) due to strongholds in some legacy drugs. Its lower valuation compared to its peers and str...
- Pharma attractive again for investorsValuations are at multi-year lows; sector’s expected to remain resilient amid current downturn.
- After Market: Tata Motors, BPCL crack; 223 stocks ready to look upMarket succumbed to profit booking as investors turned cautious ahead of election outcome.
- Siddhartha Khemka of MOFSL is bullish on these 3 corporate banksMetal packs have been the single biggest drivers of Nifty earnings for the quarter, says Khemka
- Promoter holdings remain same as India pharma battles rough seasIn two cases - Dr Reddy's and Strides Shasun -promoter stakes have increased marginally.
- Dr Reddy’s Laboratories pins hopes on launches after sharp fall in Q4 profitThe stock suffered a fall immediately after the announcement of results but recovered to close with a gain of 3.65% at Rs 2,973.85 on BSE.
- Planning to dump Dr Reddy's from your portfolio post Q4 numbers? Think twiceMost global brokerage firms maintained a positive view on the stock post March quarter results and CLSA has even raised its 12-month target...
- Look who moved my market on ThursdaySensex plunged over 800 points on Thursday tracking weak cues from other Asian and European markets and weak earnings by leading index cons...
- Sensex falls 499 points after hitting record high; Nifty holds 8800The Nifty ended at 8,808.90, down 143 points or 1.60 per cent. It touched an all-time high of 8,996.60 and a low of 8,775.10 in trade today.
- Brokerages bullish on Dr Reddy’s despite rouble concernsThe stock has been weak since the beginning of December. The slide has aggravated as Russia’s rouble slipped to an all-time low.
- Sensex too maintains a status quo post policy; down about 100 pointsSensex slipped over 150 points after RBI announced a status quo. The index pared some losses soon after, but is now down over 100 points.
- Dr Reddy's Laboratories reports 17% net profit drop in July-September quarter, spent 12% of revenues on R&DDr Reddy's stock slipped 1.11% to close at Rs 3,046 on the Bombay Stock Exchange on Wednesday as the results fell short of street expectati...
- Dr Reddy's second quarter net down 17 per cent at Rs 574.1 croreThe company reported sales of Rs 3,587 crore in the second quarter, 7% more than a year earlier, while net profit slipped 17% to Rs 574 cro...
- Sensex drops over 200 points; Nifty slips below 7,700Tracking the momentum, Nifty also slipped below its crucial psychological level of 7700, weighed down by losses in realty, banks, pharma an...
- Pharma companies like Sun Pharma, Dr Reddy's Labs likely to do wellDr Reddy's Labs (DRL) is going to be major outperformer in the pharma pack, thanks to its recent drug launches in the US market.
- Pharma sector to see healthy growth, but not for all companiesThe pharma sector is likely to maintain a healthy revenue growth rate of 20-25% for the quarter ended December 2011.
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
Load More
